8-KOther Events

VERTEX PHARMACEUTICALS INC / MA 8-K Report (Nov 14, 2002)

Filed November 14, 2002For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated filed a Form 8-K on November 14, 2002, to report on the accompanying certifications provided with their Quarterly Report on Form 10-Q for the period ending September 30, 2002. These certifications were made by the company's Principal Executive Officer, Joshua S. Boger, and Principal Financial Officer, Ian F. Smith, in compliance with Section 906 of the Sarbanes-Oxley Act of 2002. This filing is primarily procedural, indicating that the company is adhering to new regulatory requirements for financial reporting accuracy and accountability as mandated by the Sarbanes-Oxley Act. Investors can view this as a positive step towards enhanced corporate governance and transparency. The actual financial and operational details of the September 30, 2002 quarter would be found in the Form 10-Q itself, with this 8-K serving as a confirmation of the executive certifications related to that filing.

Key Highlights

  • 1Vertex Pharmaceuticals Inc. filed an 8-K on November 14, 2002.
  • 2The filing concerns the Quarterly Report on Form 10-Q for the period ending September 30, 2002.
  • 3Certifications were provided by the Principal Executive Officer (Joshua S. Boger) and Principal Financial Officer (Ian F. Smith).
  • 4These certifications are pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  • 5The filing is a procedural update regarding compliance with new regulatory requirements.
  • 6Exhibit 99.1 contains a copy of the certifications.

Frequently Asked Questions

The main purpose of this 8-K filing is to report that Vertex Pharmaceuticals Incorporated has provided certifications from its Principal Executive Officer and Principal Financial Officer regarding the accuracy of its Quarterly Report on Form 10-Q for the period ending September 30, 2002. These certifications are a requirement under Section 906 of the Sarbanes-Oxley Act of 2002.

No, this 8-K filing does not contain new financial results. It is a procedural filing confirming that the executive officers have certified the accuracy of the financial information previously reported in the Form 10-Q for the quarter ending September 30, 2002.

The Sarbanes-Oxley Act of 2002 (SOX) introduced significant reforms to corporate governance and financial disclosure standards in response to accounting scandals. Section 906 specifically requires CEOs and CFOs to personally certify the accuracy of financial reports filed with the SEC.

The financial and operational details for the quarter ending September 30, 2002, would be found in Vertex Pharmaceuticals' Quarterly Report on Form 10-Q, which this 8-K references and relates to.